Atherosclerotic lesion development in a novel ovary-intact mouse model of perimenopause

Loretta P. Mayer, Cheryl A. Dyer, Rebecca L. Eastgard, Patricia B Hoyer, Carole L. Banka

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Objective - Since the unexpected results from the Women's Health Initiative, the possible protective role of estrogen in preventing heart disease in perimenopausal and postmenopausal women is uncertain. This study examined atherosclerotic lesion development in ovariectomized versus follicle-depleted ovary-intact cholesterol-fed female low-density lipoprotein (LDL) receptor-deficient mice. Methods and Results - We studied lesion development in LDL receptor-deficient mice that were ovariectomized or follicle depleted with 4-vinylcyclohexene diepoxide (VCD) to induce ovarian failure, then treated ± exogenous 17β-estradiol via pellet implant. At 120 days after start of cholesterol feeding, the extent of lesion in aorta and innominate artery was determined. Lesion area in both locations was similar in vehicle control, VCD-treated, and ovariectomized mice. Replacement with 17β-estradiol caused lesion reduction (P<0.05) in both arterial locations, but it was most efficacious in suppressing innominate lesion area in VCD-treated mice (12.9±5.2%) compared with ovariectomized mice (40.0±6.04%). Conclusions - Endocrine status associated with the follicle-depleted ovary influences exogenous estradiol effects during the development of atherosclerotic lesions and, in particular, inhibits lesion progression in the innominate artery.

Original languageEnglish (US)
Pages (from-to)1910-1916
Number of pages7
JournalArteriosclerosis, Thrombosis, and Vascular Biology
Volume25
Issue number9
DOIs
StatePublished - Sep 2005

Fingerprint

Perimenopause
Ovary
Brachiocephalic Trunk
Estradiol
LDL Receptors
Cholesterol
Women's Health
Aorta
Heart Diseases
Estrogens
4-vinyl-1-cyclohexene dioxide

Keywords

  • Atherosclerosis
  • Estrogen supplementation
  • Perimenopause model

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Atherosclerotic lesion development in a novel ovary-intact mouse model of perimenopause. / Mayer, Loretta P.; Dyer, Cheryl A.; Eastgard, Rebecca L.; Hoyer, Patricia B; Banka, Carole L.

In: Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 25, No. 9, 09.2005, p. 1910-1916.

Research output: Contribution to journalArticle

Mayer, Loretta P. ; Dyer, Cheryl A. ; Eastgard, Rebecca L. ; Hoyer, Patricia B ; Banka, Carole L. / Atherosclerotic lesion development in a novel ovary-intact mouse model of perimenopause. In: Arteriosclerosis, Thrombosis, and Vascular Biology. 2005 ; Vol. 25, No. 9. pp. 1910-1916.
@article{4de391e08ec142a3943bd0dd8fb97201,
title = "Atherosclerotic lesion development in a novel ovary-intact mouse model of perimenopause",
abstract = "Objective - Since the unexpected results from the Women's Health Initiative, the possible protective role of estrogen in preventing heart disease in perimenopausal and postmenopausal women is uncertain. This study examined atherosclerotic lesion development in ovariectomized versus follicle-depleted ovary-intact cholesterol-fed female low-density lipoprotein (LDL) receptor-deficient mice. Methods and Results - We studied lesion development in LDL receptor-deficient mice that were ovariectomized or follicle depleted with 4-vinylcyclohexene diepoxide (VCD) to induce ovarian failure, then treated ± exogenous 17β-estradiol via pellet implant. At 120 days after start of cholesterol feeding, the extent of lesion in aorta and innominate artery was determined. Lesion area in both locations was similar in vehicle control, VCD-treated, and ovariectomized mice. Replacement with 17β-estradiol caused lesion reduction (P<0.05) in both arterial locations, but it was most efficacious in suppressing innominate lesion area in VCD-treated mice (12.9±5.2{\%}) compared with ovariectomized mice (40.0±6.04{\%}). Conclusions - Endocrine status associated with the follicle-depleted ovary influences exogenous estradiol effects during the development of atherosclerotic lesions and, in particular, inhibits lesion progression in the innominate artery.",
keywords = "Atherosclerosis, Estrogen supplementation, Perimenopause model",
author = "Mayer, {Loretta P.} and Dyer, {Cheryl A.} and Eastgard, {Rebecca L.} and Hoyer, {Patricia B} and Banka, {Carole L.}",
year = "2005",
month = "9",
doi = "10.1161/01.ATV.0000175767.46520.6a",
language = "English (US)",
volume = "25",
pages = "1910--1916",
journal = "Arteriosclerosis, Thrombosis, and Vascular Biology",
issn = "1079-5642",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Atherosclerotic lesion development in a novel ovary-intact mouse model of perimenopause

AU - Mayer, Loretta P.

AU - Dyer, Cheryl A.

AU - Eastgard, Rebecca L.

AU - Hoyer, Patricia B

AU - Banka, Carole L.

PY - 2005/9

Y1 - 2005/9

N2 - Objective - Since the unexpected results from the Women's Health Initiative, the possible protective role of estrogen in preventing heart disease in perimenopausal and postmenopausal women is uncertain. This study examined atherosclerotic lesion development in ovariectomized versus follicle-depleted ovary-intact cholesterol-fed female low-density lipoprotein (LDL) receptor-deficient mice. Methods and Results - We studied lesion development in LDL receptor-deficient mice that were ovariectomized or follicle depleted with 4-vinylcyclohexene diepoxide (VCD) to induce ovarian failure, then treated ± exogenous 17β-estradiol via pellet implant. At 120 days after start of cholesterol feeding, the extent of lesion in aorta and innominate artery was determined. Lesion area in both locations was similar in vehicle control, VCD-treated, and ovariectomized mice. Replacement with 17β-estradiol caused lesion reduction (P<0.05) in both arterial locations, but it was most efficacious in suppressing innominate lesion area in VCD-treated mice (12.9±5.2%) compared with ovariectomized mice (40.0±6.04%). Conclusions - Endocrine status associated with the follicle-depleted ovary influences exogenous estradiol effects during the development of atherosclerotic lesions and, in particular, inhibits lesion progression in the innominate artery.

AB - Objective - Since the unexpected results from the Women's Health Initiative, the possible protective role of estrogen in preventing heart disease in perimenopausal and postmenopausal women is uncertain. This study examined atherosclerotic lesion development in ovariectomized versus follicle-depleted ovary-intact cholesterol-fed female low-density lipoprotein (LDL) receptor-deficient mice. Methods and Results - We studied lesion development in LDL receptor-deficient mice that were ovariectomized or follicle depleted with 4-vinylcyclohexene diepoxide (VCD) to induce ovarian failure, then treated ± exogenous 17β-estradiol via pellet implant. At 120 days after start of cholesterol feeding, the extent of lesion in aorta and innominate artery was determined. Lesion area in both locations was similar in vehicle control, VCD-treated, and ovariectomized mice. Replacement with 17β-estradiol caused lesion reduction (P<0.05) in both arterial locations, but it was most efficacious in suppressing innominate lesion area in VCD-treated mice (12.9±5.2%) compared with ovariectomized mice (40.0±6.04%). Conclusions - Endocrine status associated with the follicle-depleted ovary influences exogenous estradiol effects during the development of atherosclerotic lesions and, in particular, inhibits lesion progression in the innominate artery.

KW - Atherosclerosis

KW - Estrogen supplementation

KW - Perimenopause model

UR - http://www.scopus.com/inward/record.url?scp=24144437357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24144437357&partnerID=8YFLogxK

U2 - 10.1161/01.ATV.0000175767.46520.6a

DO - 10.1161/01.ATV.0000175767.46520.6a

M3 - Article

C2 - 15994440

AN - SCOPUS:24144437357

VL - 25

SP - 1910

EP - 1916

JO - Arteriosclerosis, Thrombosis, and Vascular Biology

JF - Arteriosclerosis, Thrombosis, and Vascular Biology

SN - 1079-5642

IS - 9

ER -